Hematopoiesis News

[Emmes (PR Newswire, Inc.)] Emmes announced that it provided the Phase III clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant.

[British Journal of Haematology] Investigators monitored fetal haemoglobin levels in 25 preterm neonates until 36 weeks of post‐menstrual age; patients received repeated red blood cell (RBC) units from allogeneic cord blood (cord‐RBCs) or from adult donors, depending on whether cord‐RBCs were available.